Literature DB >> 6408256

Loose stools during auranofin treatment: clinical study and some pathogenetic possibilities.

P L van Riel, F W Gribnau, L B van de Putte, S H Yap.   

Abstract

Loose stools, one of the most frequent adverse reactions ascribed to the orally absorbed gold compound auranofin (AF), was studied during a longterm trial. At some time during the study 44% of 25 patients reported the occurrence of loose stools. No infection or signs of malabsorption were found; nor were loose stools caused by the presence of osmotically active substances in the gut lumen. Arguments for a direct effect of AF on the ion and water absorption in the intestine are given. Although no morphological studies on biopsy material are available, the known side effects of the drug do not seem to warrant its discontinuation in suitable patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6408256

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  The moderate intestinal side effects of auranofin do not require prophylactic therapy with a bulkforming agent. Dutch Ridaura Study Group.

Authors:  H J van Beusekom; M A van de Laar; M J Franssen; J A van Valburg; W P Gijzel; J E Couvée
Journal:  Clin Rheumatol       Date:  1997-09       Impact factor: 2.980

2.  Investigation of auranofin-induced diarrhoea.

Authors:  R Behrens; M Devereaux; B Hazleman; K Szaz; J Calvin; G Neale
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

3.  Serum gold concentrations during treatment with auranofin.

Authors:  P L Van Riel; F W Gribnau; L B Van de Putte; C W Arts; A Van Aernsbergen
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980

Review 4.  Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition.

Authors:  Carmelo Scarpignato; Ingvar Bjarnason
Journal:  Curr Gastroenterol Rep       Date:  2019-11-13

Review 5.  Management of adverse effects of disease-modifying antirheumatic drugs.

Authors:  M J Wijnands; P L van Riel
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

6.  Comparison of auranofin and aurothioglucose in the treatment of rheumatoid arthritis: a single blind study.

Authors:  P L van Riel; L B van de Putte; F W Gribnau; K D Macrae
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

Review 7.  Worldwide clinical experience with auranofin.

Authors:  R W Morris; D S Cole; J Horton; M A Heuer; R G Pietrusko
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

Review 8.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

9.  Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate.

Authors:  D Lewis; H A Capell
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

10.  Effect of oral gold salt therapy on bile acid absorption in rheumatoid arthritis patients.

Authors:  M Magaró; L Altomonte; L Mirone; A Zoli; G Corvino; G Carelli
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.